Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating an investigational drug called ALN-HSD for adults with Metabolic Dysfunction-Associated SteatoHepatitis MASH, a liver condition marked by fat buildup, inflammation, and scarring that can lead to cirrhosis and liver failure. This Phase 2 study aims to understand how ALN-HSD affects liver scarring and inflammation in participants who have genetic risk factors for MASH. Participants are randomly assigned in a 11 ratio to receive either ALN-HSD or a placebo. The study is double-blind and quadruple-masked, meaning neither participants nor researchers know who receives the active drug or placebo. Treatment is administered according to the study protocol over a period of 52 weeks, with follow-up monitoring extending to 84 weeks to assess safety. During the study, participants will undergo various assessments including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and genetic evaluations. Researchers will track changes in liver fibrosis and inflammation as well as the presence of drug metabolites in blood samples. Safety is monitored throughout the study and beyond the treatment period. The total duration of participation is up to 84 weeks.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide compared to placebo in people with opioid use disorder OUD who are also receiving buprenorphine treatment, with or without naloxone. This Phase 2 study includes participants with mild to severe OUD and aims to assess abstinence from opioid use over a defined period. The study has two parts Part A involves a double-blind treatment phase followed by an open-label extension, while Part B includes only open-label treatment. Participants receive brenipatide or placebo by subcutaneous injection alongside buprenorphine administered under the tongue or in the cheek. Each participant enrolls in only one part, with treatment durations up to approximately 144 weeks in Part A and 116 weeks in Part B. Participants attend regular study visits for assessments, including urine drug screens and self-reports to measure opioid abstinence, adherence to buprenorphine, and changes in craving and quality of life. Other evaluations include monitoring for overdose events, healthcare utilization, body measurements, and blood pressure. Safety is tracked through laboratory tests and antibody monitoring, with the overall study lasting up to several years depending on enrollment timing.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide compared with placebo in adults with persistent obesity or overweight. Participants may have type 2 diabetes or not, and all are on stable background therapy with a weekly incretin. This phase 3 randomized, double-blind study aims to understand the effects of eloralintide on body weight and related health outcomes. Participants will be randomly assigned to receive one of four doses of eloralintide or a placebo, all given by subcutaneous injection once weekly. The study treatment period lasts for 64 weeks, during which participants receive their assigned injections. This is a parallel group study, meaning each participant receives only one assigned treatment throughout the trial. Participant involvement spans about 80 weeks, including screening, treatment, and follow-up. Researchers will monitor changes in body weight, waist circumference, blood pressure, blood sugar, insulin, kidney function, inflammation markers, and quality of life using questionnaires. Safety and medication use will also be tracked. Visits and assessments will occur regularly to evaluate the treatment effects and participant well-being.
Actively Recruiting
Researchers are evaluating the safety, tolerability, patient outcomes, imaging biomarkers, and treatment satisfaction of ocrelizumab combined with recombinant human hyaluronidase when given as a subcutaneous injection in adults with relapsing or primary progressive multiple sclerosis who have switched from another approved anti-CD20 therapy. This phase 4 study focuses on participants who previously received ofatumumab, ublituximab-xiiy, or intravenous ocrelizumab treatments. Participants will receive two doses of ocrelizumab subcutaneously 920 milligrams on Day 1 and again at Week 24. The study observes this treatment given after switching from another anti-CD20 therapy, monitoring effects over time. The study uses a single group design without a placebo or comparison arm. During the study, participants will undergo brain MRI scans to measure changes in lesions at baseline, Week 24, and Week 48. Researchers will also assess adverse events, B-cell counts, and various treatment satisfaction questionnaires. The study includes assessments of disability and quality of life at multiple timepoints. Participation lasts up to 48 weeks, with safety and efficacy monitored throughout the study.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orelabrutinib, a brain-penetrating BTK inhibitor, in people with Primary Progressive Multiple Sclerosis PPMS. This is a Phase 3, randomized, double-blind, parallel-group, multicenter study comparing orelabrutinib with a placebo. Approximately 705 participants aged 18 to 60 with documented disability progression will be enrolled globally. Participants will be randomly assigned in a 21 ratio to receive either oral orelabrutinib or a placebo. Treatment will last approximately 30 to 60 months, with a minimum duration of 12 months. The study includes two groups one receiving orelabrutinib and the other receiving placebo, both taken orally. Throughout the study, participants will undergo regular assessments including disability progression measurements confirmed over 12 and 24 weeks, MRI scans, and tests such as the 9-hole Peg Test and Timed 25-Foot Walk Test. Safety will be monitored continuously, and the primary outcome is time to confirmed disability progression over about 120 weeks. Participants will be followed up for up to 5 years to evaluate the treatment effects and safety.
Actively Recruiting
Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.
Actively Recruiting
Researchers are studying targeted therapies for adults with moderately to severely active Rheumatoid Arthritis RA, a chronic condition causing joint pain, stiffness, swelling, and loss of function. This Phase 2 trial aims to evaluate the safety and effectiveness of three different treatment approaches compared to placebo in participants who have not responded well to one or two prior biologic or targeted synthetic disease-modifying antirheumatic drugs btsDMARDs. The study includes three substudies Lutikizumab monotherapy versus placebo, Ravagalimab monotherapy versus placebo, and a combination of Lutikizumab and Ravagalimab versus placebo. Treatments are given as subcutaneous injections with participants randomized to receive either active drugs or matching placebo doses. Approximately 180 participants will enroll and receive study treatments during the trial. Participants will have regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted. The main outcomes measured include the percentage of participants achieving significant improvement in RA symptoms American College of Rheumatology 50% response at 12 weeks and tracking adverse events up to about 22 weeks. The study continues until November 2027 with ongoing safety and efficacy monitoring.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
1-10 of 13
1